Vitamin K2 Supplementation and Vascular Calcification

• Status: Completed
• Trial end date: 2017-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Vascular calcification is the leading cause of death in patients with end stage renal disease (ESRD) in hemodialysis. The protein matrix Gla vitamin K dependent (MGP) is a potent inhibitor of the vascular calcification. Objective: To evaluate the effect of vitamin K2 on vascular calcification in patients on hemodialysis. Materials and Methods: A prospective, randomized, double-blind study will be performed. The study subjects will be divided into a control (1000 µl of saline) or treated group (1000 µl containing 2000 µg of Vitamin K2). Vitamin K2 will be administered three times a week intravenously at the end of each dialysis session. Blood samples for biochemical determinations and vascular calcification will be assessed before and after 6 months of treatment through carotid Doppler ultrasound.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Catholic University of Salta
• Treatments: Vitamin K; Vitamin K 2

Criteria

Inclusion Criteria:

• Men or women ≥18 years old

• A period not less than 6 months in HD

• Life expectancy ≥ 18 months

• Signed informed consent

Exclusion Criteria:

• Patients under treatment with phosphorus chelators

• Patients who do not want to participate in the study